Documentary record · APPROVAL

Isembyld (apitegromab-mstn) approved as the first SMA therapy that targets muscle loss

APPROVED

Event date

September 11, 2026

Jurisdiction

United States

Issuing body

U.S. Food and Drug Administration

Action type

APPROVAL

Lifecycle state

APPROVED

Verification date

15 September 2026

A marketing approval for add-on use. It does not determine coverage.

What this establishes

  • FDA approved Isembyld for spinal muscular atrophy in adults and children aged 2 and older who are already receiving an SMN2-targeted treatment.
  • In a 52-week randomized trial of 188 participants (primary analysis in 156 aged 2–12), treated patients improved on the Hammersmith Functional Motor Scale Expanded while placebo patients declined; 34.2% versus 13.5% had a clinically meaningful improvement.
  • Labeling notes an increased risk of fractures, including serious fractures, and potential fetal harm.
  • The product received Fast Track, Orphan Drug and Rare Pediatric Disease designations.

What this does not establish

  • Benefit in populations not studied in the trial.
  • Coverage.

Why it matters

The first approved therapy aimed at muscle rather than motor-neuron survival in SMA, approved as an add-on — which makes combination cost and access the next question.

Primary source

Register: the record store · record id fda-isembyld-sma-2026-09-11.